A. Muzio

Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).

M. Mencoboni, E. Aitini, B. Castagneto, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.

S. Novello, J. Jassem, M. Tiseo, 2018, The Lancet. Oncology.

Analysis of survival of patients with metastatic malignant pleural mesothelioma

F. Grosso, A. Billé, L. Harling, 2020, Tumori.

Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study

C. Bosetti, P. Allavena, G. Ceresoli, 2022, International journal of molecular sciences.

Cisplatin and Gemcitabine in Malignant Pleural Mesothelioma: A Phase II Study

S. Bretti, B. Castagneto, G. Numico, 2005, American journal of clinical oncology.

Malignant pleural mesothelioma: Germline variants in DNA repair genes may steer tailored treatment.

G. Scagliotti, E. Migliore, G. Matullo, 2022, European journal of cancer.

A fourth case of BCR-FGFR1 positive CML-like disease with t(8;22) translocation showing an extensive deletion on the derivative chromosome 8p.

A. Levis, G. Saglio, E. Giugliano, 2002, The hematology journal : the official journal of the European Haematology Association.

Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma

G. Ceresoli, M. Mencoboni, F. Grosso, 2017, Oncology Research and Treatment.

191 Pemetrexed in combination with carboplatin in elderly patients with malignant pleural mesothelioma

A. Ceribelli, M. Marangolo, G. Ceresoli, 2006 .

Pemetrexed (MTA) and carboplatin (CBDCA) in the treatment of advanced pleural mesothelioma (MPM).

M. Mencoboni, B. Castagneto, R. Buosi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (MPM).

S. Novello, J. Jassem, M. Tiseo, 2015 .